Tehran (IP) - Iran’s domestically-developed and produced Noora coronavirus vaccine has entered the third stage of human trial after the IRGC chief commander got the jab.

Iran PressIran News: In the third human trial phase of the new Iranian coronavirus vaccine, which began on Sunday in a ceremony attended by the Chief Commander of the Islamic Revolution Guard Corps (IRGC), Major General Hossein Salami, and Iran’s Health Minister Bahram Einollahi on the eve of the second martyrdom anniversary of Iran’s legendary anti-terror commander Lt Gen Qassem Soleimani, 10,000 doses are to be injected into volunteers.

Major General Salami received the vaccine jab in the ceremony of the beginning of the third phase of clinical studies of the Noora vaccine.

Speaking at the ceremony, Hassan Abolghasemi, the president of Baqiyatallah University of Medical Sciences, said: “Noora vaccine is a recombinant vaccine that was tested on 70 volunteers in the first phase and 300 on the second phase. In the first phase of the human test, the Noora vaccine was proven to be safe and the immunization was evaluated in the second phase, and about ten thousand people will receive the vaccine in the third phase.”

According to him, five million doses of the Noora vaccine, produced by Baqiyatallah University of Medical Sciences with the support of the IRGC, are ready and will be delivered to the Ministry of Health and Medical Education once the third stage of human trial has been carried out.

At the ceremony, the minister of health said that the Iranian people showed their power to fight against the coronavirus in the nationwide vaccination during the past 4 months.

Einollahi added: “People came to the scene and we injected 120 million doses of vaccine in 4 months.”

Related News:

Iranian Noora vaccine complies with FDA standards

Noora vaccine was put on display during a ceremony in Tehran on June 27 in the presence of Major General Salami, Iran’s former health minister Saeed Namaki as well as other Iranian health officials.

Preliminary studies of this recombinant anti-corona vaccine, produced by Iranian researchers at Baqiyatallah University of Medical Sciences and Imam Hussein University (AS), began in March 2020.

After successfully conducting animal tests and passing all the quantitative and qualitative evaluations of the Food and Drug Administration, Noora vaccine was able to receive the code of ethics in research from the National Vaccine Committee.

The recombinant vaccine then entered the first stage of the human trial after 16 months of research work by Iranian scientists.

Its first dose was injected into the chief medical officer of Baqiyatallah Hospital, Hossein Samadinia.

Noora vaccine’s mass production line is under development.

The process of learning about and developing an investigational medicine is divided into different phases. At first, very few people receive the medicine being studied. The number of people participating in clinical studies grows along with our understanding of the investigational medicine, and the research continues as long as the potential benefits outweigh the risks.

As Iran began marking the second anniversary of the US assassination of the top general Qassem Soleimani, the IRGC is also scheduled to conduct the largest-scale ‘Pious Help’ exercise and distribute 2 million livelihood packages throughout the country.


Read More:

Clinical trial of Noora corona vaccine successfully completed

'Noora' COVID-19 vaccine to be given to world's oppressed: IRGC official

Iran starts clinical trial of homemade 'Noora' COVID-19 vaccine